Bibliografía científicaBibliografía científica

En esta sección encontrará una selección de las publicaciones científicas sobre los Trastornos del Movimiento para los 11 diferentes tipos establecidos por la International Parkinson & Movement Disorder Society. Se han seleccionado sólo aquellas publicaciones que presenten el término de búsqueda en el título (inglés).

Los artículos presentados incluyen aquellos publicados desde enero de 2010. El listado de publicaciones de actualizará mensualmente. Si lo desea, puede recibir una alerta de la actualización por correo electrónico. Para ello ha de registrarse.

Búsqueda
Enfermedad de Parkinson y Parkinsonismo Parkinson’s disease & Parkinsonism 2601 artículos Viendo del 1 al 40 de 2601 artículos
Pub MED

Effects of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease: a prospective controlled study.NUEVO

Vercruysse S, Vandenberghe W, Münks L, Nuttin B, Devos H, Nieuwboer A.
J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):871-7. doi: 10.1136/jnnp-2013-306336.
Pub MED

Effects of deep brain stimulation frequency on bradykinesia of Parkinson's disease.NUEVO

Huang H, Watts RL, Montgomery EB Jr.
Mov Disord. 2014 Feb;29(2):203-6. doi: 10.1002/mds.25773.
Pub MED

Predictors of cognitive impairment in an early stage Parkinson's disease cohort.NUEVO

Hu MT, Szewczyk-Królikowski K, Tomlinson P, Nithi K, Rolinski M, Murray C, Talbot K, Ebmeier KP, Mackay CE, Ben-Shlomo Y.
Mov Disord. 2014 Mar;29(3):351-9. doi: 10.1002/mds.25748.
Pub MED

Disparities in access to deep brain stimulation surgery for Parkinson disease: interaction between African American race and Medicaid use.NUEVO

Chan AK, McGovern RA, Brown LT, Sheehy JP, Zacharia BE, Mikell CB, Bruce SS, Ford B, McKhann GM 2nd.
JAMA Neurol. 2014 Mar;71(3):291-9. doi: 10.1001/jamaneurol.2013.5798.
Pub MED

Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.NUEVO

Sapkota S, Gee M, Sabino J, Emery D, Camicioli R.
Mov Disord. 2014 Mar;29(3):368-74. doi: 10.1002/mds.25798.
Pub MED

Association between PITX3 promoter polymorphism and risk of Parkinson's disease: the impact of ethnicity and onset age.NUEVO

Qiu G, Fu C, Liang GH.
Neurosci Lett. 2014 Feb 21;561:128-33. doi: 10.1016/j.neulet.2013.12.054.
Pub MED

The role of vitamin D levels and vitamin D receptor polymorphism on Parkinson's disease in the Faroe Islands.NUEVO

Petersen MS, Bech S, Christiansen DH, Schmedes AV, Halling J.
Neurosci Lett. 2014 Feb 21;561:74-9. doi: 10.1016/j.neulet.2013.12.053.
Pub MED

BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease.NUEVO

Białecka M, Kurzawski M, Roszmann A, Robowski P, Sitek EJ, Honczarenko K, Mak M, Deptuła-Jarosz M, Gołąb-Janowska M, Droździk M, Sławek J.
Neurosci Lett. 2014 Feb 21;561:86-90. doi: 10.1016/j.neulet.2013.12.051.
Pub MED

Feasibility of a web-based survey of hallucinations and assessment of visual function in patients with Parkinson's disease.NUEVO

Jackson ML, Bex PJ, Ellison JM, Wicks P, Wallis J.
Interact J Med Res. 2014 Jan 6;3(1):e1. doi: 10.2196/ijmr.2744.
Pub MED

Importance of nondopaminergic features in evaluating disease severity of Parkinson disease.NUEVO

van der Heeden JF, Marinus J, Martinez-Martin P, van Hilten JJ.
Neurology. 2014 Feb 4;82(5):412-8. doi: 10.1212/WNL.0000000000000087.
Pub MED

Comment: why do nondopaminergic features in Parkinson disease matter?NUEVO

Maetzler W.
Neurology. 2014 Feb 4;82(5):417. doi: 10.1212/WNL.0000000000000095.
Pub MED

EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson's disease.NUEVO

Jia Y, Mo SJ, Feng QQ, Zhan ML, OuYang LS, Chen JC, Ma YX, Wu JJ, Lei WL.
J Mol Neurosci. 2014 May;53(1):117-24. doi: 10.1007/s12031-013-0208-0.
Pub MED

Conceptualizing and prioritizing clinical trial outcomes from the perspectives of people with Parkinson's disease versus health care professionals: a concept mapping study.NUEVO

Sjödahl Hammarlund C, Nilsson MH, Idvall M, Rosas SR, Hagell P.
Qual Life Res. 2014 Aug;23(6):1687-700. doi: 10.1007/s11136-013-0614-3.
Pub MED

Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.NUEVO

Müller T, Muhlack S.
J Neural Transm (Vienna). 2014 Jun;121(6):643-8. doi: 10.1007/s00702-013-1155-1.
Pub MED

Sexual dimorphism in xenobiotic genetic variants-mediated risk for Parkinson's disease.NUEVO

Kumudini N, Uma A, Naushad SM, Mridula R, Borgohain R, Kutala VK.
Neurol Sci. 2014 Jun;35(6):897-903. doi: 10.1007/s10072-013-1622-3.
Pub MED

Effects of the root bark of Paeonia suffruticosa on mitochondria-mediated neuroprotection in an MPTP-induced model of Parkinson's disease.NUEVO

Kim HG, Park G, Piao Y, Kang MS, Pak YK, Hong SP, Oh MS.
Food Chem Toxicol. 2014 Mar;65:293-300. doi: 10.1016/j.fct.2013.12.037.
Pub MED

Parkinson's disease: a review.NUEVO

Beitz JM.
Front Biosci (Schol Ed). 2014 Jan 1;6:65-74. Review.
Pub MED

Disruption of the blood-brain barrier in Parkinson's disease: curse or route to a cure?NUEVO

Lee H, Pienaar IS.
Front Biosci (Landmark Ed). 2014 Jan 1;19:272-80. Review.
Pub MED

Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?NUEVO

Bisaglia M, Filograna R, Beltramini M, Bubacco L.
Ageing Res Rev. 2014 Jan;13:107-14. doi: 10.1016/j.arr.2013.12.009. Review.
Pub MED

PINK1 and its familial Parkinson's disease-associated mutation regulate brain vascular endothelial inflammation.NUEVO

Yunfu W, Guangjian L, Ping Z, Yanpeng S, Xiaoxia F, Wei H, Jiang Y, Jingquan H, Songlin W, Hongyan Z, Yong L, Shi C.
J Mol Neurosci. 2014 May;53(1):109-16. doi: 10.1007/s12031-013-0207-1.
Pub MED

An update on Parkinson's disease: improving patient outcomes.NUEVO

Kremens D, Hauser RA, Dorsey ER.
Am J Med. 2014 Jan;127(1):S3. doi: 10.1016/j.amjmed.2013.06.016.
Pub MED

A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.NUEVO

Ambrosi G, Cerri S, Blandini F.
J Neural Transm (Vienna). 2014 Aug;121(8):849-59. doi: 10.1007/s00702-013-1149-z. Review.
Pub MED

Cause-specific mortality among spouses of Parkinson disease patients.NUEVO

Nielsen M, Hansen J, Ritz B, Nordahl H, Schernhammer E, Wermuth L, Rod NH.
Epidemiology. 2014 Mar;25(2):225-32. doi: 10.1097/EDE.0000000000000042.
Pub MED

Amide-type adduct of dopamine - plausible cause of Parkinson diseases.NUEVO

Liu X, Yamada N, Osawa T.
Subcell Biochem. 2014;77:49-60. doi: 10.1007/978-94-007-7920-4_4. Review.
Pub MED

The future of cell therapies and brain repair: Parkinson's disease leads the way.NUEVO

Petit GH, Olsson TT, Brundin P.
Neuropathol Appl Neurobiol. 2014 Feb;40(1):60-70. doi: 10.1111/nan.12110. Review.
Pub MED

Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?NUEVO

García AM, Redondo M, Martinez A, Gil C.
Curr Med Chem. 2014 Apr;21(10):1171-87. Review.
Pub MED

Current Challenges Towards the Development of a Blood Test for Parkinson's Disease.NUEVO

Santiago JA, Potashkin JA.
Diagnostics (Basel). 2014 Oct 22;4(4):153-64. doi: 10.3390/diagnostics4040153. Review.
Pub MED

Effects of Deep Brain Stimulation on Pausing During Spontaneous Speech in Parkinson's Disease.NUEVO

Ahn JS, Van Lancker Sidtis D, Sidtis JJ.
J Med Speech Lang Pathol. 2014;21(3):179-186.
Pub MED

Prevalence of depression in Parkinson's disease patients in Ethiopia.NUEVO

Worku DK, Yifru YM, Postels DG, Gashe FE.
J Clin Mov Disord. 2014 Dec 12;1:10. doi: 10.1186/s40734-014-0010-3.
Pub MED

Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort.NUEVO

Okun MS, Wu SS, Jennings D, Marek K, Rodriguez RL, Fernandez HH.
J Clin Mov Disord. 2014 Nov 26;1:8. doi: 10.1186/2054-7072-1-8.
Pub MED

What light have resting state fMRI studies shed on cognition and mood in Parkinson's disease?NUEVO

YorkWilliams S, Poston KL.
J Clin Mov Disord. 2014 Oct 29;1:4. doi: 10.1186/2054-7072-1-4. Review.
Pub MED

[F0 characteristics in Parkinsonian speech: Contrast between the effect of hypodopaminergy due to Parkinson's disease and that of the therapeutic delivery of L-Dopa].NUEVO

Ghio A, Robert D, Grigoli C, Mas M, Delooze C, Mercier C, Viallet F.
Rev Laryngol Otol Rhinol (Bord). 2014;135(2):63-70. French.
Pub MED

Distributions of susceptibility loci of Parkinson's disease and multiple sclerosis on human chromosomes.NUEVO

Saadat M.
EXCLI J. 2014 Jun 24;13:724-7. No abstract available.
Pub MED

Differential Changes in Postsynaptic Density Proteins in Postmortem Huntington's Disease and Parkinson's Disease Human Brains.NUEVO

Fourie C, Kim E, Waldvogel H, Wong JM, McGregor A, Faull RL, Montgomery JM.
J Neurodegener Dis. 2014;2014:938530. doi: 10.1155/2014/938530.
Pub MED

Objective Automatic Assessment of Rehabilitative Speech Treatment in Parkinson's Disease.NUEVO

Tsanas A, Little MA, Fox C, Ramig LO.
IEEE Trans Neural Syst Rehabil Eng. 2014 Jan;22(1):181-90. doi: 10.1109/TNSRE.2013.2293575.
Pub MED

Cognitive impairment in Parkinson's disease: more than a frontostriatal dysfunction.NUEVO

Galtier I, Nieto A, Lorenzo JN, Barroso J.
Span J Psychol. 2014 Oct 28;17:E68. doi: 10.1017/sjp.2014.69.
Pub MED

[Molecular basis of Parkinson's disease linked with mutations in the LRRK2 gene].NUEVO

Pchelina SN, emel'ianov AK, Usenko TS.
Mol Biol (Mosk). 2014 Jan-Feb;48(1):3-14. Review. Russian.
Pub MED

Driving errors in Parkinson's disease: moving closer to predicting on-road outcomes.NUEVO

Classen S, Brumback B, Monahan M, Malaty II, Rodriguez RL, Okun MS, McFarland NR.
Am J Occup Ther. 2014 Jan-Feb;68(1):77-85. doi: 10.5014/ajot.2014.008698.
Pub MED

Systematic review of the effectiveness of occupational therapy-related interventions for people with Parkinson's disease.NUEVO

Foster ER, Bedekar M, Tickle-Degnen L.
Am J Occup Ther. 2014 Jan-Feb;68(1):39-49. doi: 10.5014/ajot.2014.008706. Review.
Pub MED

Prepulse inhibition is associated with attention, processing speed, and 123I-FP-CIT SPECT in Parkinson's disease.NUEVO

Zoetmulder M, Biernat HB, Nikolic M, Korbo L, Friberg L, Jennum PJ.
J Parkinsons Dis. 2014;4(1):77-87. doi: 10.3233/JPD-130307.
Viendo del 1 al 40 de 2601 artículos
Con el aval de:

Sociedad Española de Neurología

Sociedad Española
de Neurología
En colaboración con:

Zambon

Haga click en el logo para acceder
a información acerca de Zambon
NeuroAcademy
Utilizamos cookies propias y de terceros para identificar la sesión del usuario y mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continúa navegando por el sitio web manifiesta consentir su instalación y uso conforme lo anterior. Puede cambiar la configuración y obtener más información aquí.